Based in Boston, Massachusetts and named after the Japanese deity that tamed fire for the good of humanity, Kojin is harnessing groundbreaking discoveries in cell-state and ferroptosis biology to develop first-in-class treatments for use in patients with cancer, and autoimmune and inflammatory diseases, among other disorders. Kojin has developed a drug-discovery platform that integrates computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to discover therapeutics that specifically modulate ferroptosis, a recently discovered and characterized cell-death mechanism. The Kojin team brings together scientific leadership in chemical biology, genetics, immunology, cancer therapeutics, drug discovery, and clinical development, as well as broad experience in biotechnology entrepreneurship.
Company Details
- Employees
- 11
- Founded
- 2020
- Address
- 451 D St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.kojintx.com
- HQ
- Boston, Massachusetts
Kojin Therapeutics Questions
Kojin Therapeutics's website is https://www.kojintx.com
Kojin Therapeutics's LinkedIn profile is https://www.linkedin.com/company/kojin-therapeutics
Kojin Therapeutics has
11 employees.
View email and phone details for 11
employees at Kojin Therapeutics.
Kojin Therapeutics's industry is
Biotechnology Research
Kojin Therapeutics's top competitors are
Beam Therapeutics,
Corner Therapeutics,
Vc-Backed Biotech Newco,
Anthos Therapeutics,
Verve Therapeutics,
Inventiva Pharma,
Xilio Therapeutics, Inc.,
Third Harmonic Bio,
Landmark Bio,
Kisbee Therapeutics.
Kojin Therapeutics's categories are Biotechnology Research
Kojin Therapeutics's founding year is 2020
